Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.

MLA

Parker, Ben, et al. “Cost-Effectiveness of the Long-Acting Regimen Cabotegravir plus Rilpivirine for the Treatment of HIV-1 and Its Potential Impact on Adherence and Viral Transmission: A Modelling Study.” PloS One, vol. 16, no. 2, Feb. 2021, p. e0245955. EBSCOhost, https://doi.org/10.1371/journal.pone.0245955.

APA

Parker, B., Ward, T., Hayward, O., Jacob, I., Arthurs, E., Becker, D., Anderson, S.-J., Chounta, V., & Van de Velde, N. (2021). Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study. PloS One, 16(2), e0245955. https://doi.org/10.1371/journal.pone.0245955

Chicago

Parker, Ben, Tom Ward, Olivia Hayward, Ian Jacob, Erin Arthurs, Debbie Becker, Sarah-Jane Anderson, Vasiliki Chounta, and Nicolas Van de Velde. 2021. “Cost-Effectiveness of the Long-Acting Regimen Cabotegravir plus Rilpivirine for the Treatment of HIV-1 and Its Potential Impact on Adherence and Viral Transmission: A Modelling Study.” PloS One 16 (2): e0245955. doi:10.1371/journal.pone.0245955.